Belrestotug

DRUG5 trials

Sponsors

GlaxoSmithKline

Conditions

Lung Cancer, Non-Small CellNeoplasmsNeoplasms, Head and Neck

Phase 1

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active, not recruitingNCT04446351

GlaxoSmithKlineNeoplasms

Start: 2020-06-25End: 2026-12-31Updated: 2025-10-27

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Active, not recruitingNCT05277051

GlaxoSmithKlineNeoplasms

Start: 2022-03-22End: 2027-08-31Updated: 2026-03-23

Phase 2

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Active, not recruitingNCT05565378

GlaxoSmithKlineLung Cancer, Non-Small Cell

Start: 2022-10-14End: 2027-02-26Updated: 2026-01-08

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Active, not recruitingNCT06062420

GlaxoSmithKlineNeoplasms, Head and Neck

Start: 2023-11-14End: 2027-07-22Updated: 2026-01-09

Phase 3

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Active, not recruitingNCT06472076

GlaxoSmithKlineLung Cancer, Non-Small Cell

Start: 2024-06-10End: 2027-02-02Updated: 2025-09-10

Related Papers

488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-015 citations